Coronavirus: Is US Trying To Lure German Vaccine Firm?

Representational Pic

BERLIN - Berlin is trying to stop Wash­ington from persuading a German company seeking a coronavirus vac­cine to move its research to the United States, prompting German politicians to insist no country should have a mo­nopoly on any future vaccine.

German government sources told Reuters on Sunday that the US ad­ministration was looking into how it could gain access to a potential vac­cine being developed by a German firm, CureVac.

Earlier, the Welt am Sonntag German newspaper reported that US President Donald Trump had offered funds to lure Cure­Vac to the United States, and the German government was mak­ing counter-offers to tempt it to stay.

A US official said: “This story is wildly overplayed ... We will con­tinue to talk to any company that claims to be able to help. And any solution found would be shared with the world.”

A German Health Ministry spokeswoman, confirming a quote in the newspaper, said: “The Ger­man government is very interested in ensuring that vaccines and ac­tive substances against the new coronavirus are also developed in Germany and Europe.”

“In this regard, the government is in intensive exchange with the company CureVac,” she added.

Welt am Sonntag quoted an un­identified German government source as saying Trump was trying to secure the scientists’ work exclu­sively, and would do anything to get a vaccine for the United States, “but only for the United States.”

Follow this link to join our WhatsApp group: Join Now

Be Part of Quality Journalism

Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast.



Leave a Reply

Your email address will not be published.